Provided by Tiger Trade Technology Pte. Ltd.

Vaxcyte, Inc.

56.48
+0.43000.77%
Post-market: 56.480.00000.00%19:49 EDT
Volume:2.40M
Turnover:135.10M
Market Cap:8.40B
PE:-7.38
High:57.00
Open:56.76
Low:55.84
Close:56.05
52wk High:65.00
52wk Low:39.87
Shares:148.81M
Float Shares:136.00M
Volume Ratio:1.72
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.6496
EPS(LYR):-5.6333
ROE:-36.51%
ROA:-22.61%
PB:3.05
PE(LYR):-10.03

Loading ...

Vaxcyte Q2 FY26 Net Loss Widens to $284.3 Million; R&D Expenses Climb to $267.9 Million

Reuters
·
Aug 06

Vaxcyte Q2 Operating Expenses USD 302.777 Million

Reuters
·
Aug 06

Vaxcyte CEO Grant Pickering Disposes of Common Shares Worth $1.02 Million

Reuters
·
Jul 29

Vaxcyte Files Form 3 Initial Beneficial Ownership Statement for Director John Markels

Reuters
·
Jul 17

Vaxcyte Names John Markels to Board as Heath Lukatch Retires

Reuters
·
Jul 16

Guggenheim Reaffirms Their Buy Rating on Vaxcyte (PCVX)

TIPRANKS
·
Jul 14

Vaxcyte to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Jul 09

Should Early VAX-A1 Trial Progress Require Action From Vaxcyte (PCVX) Investors?

Simply Wall St.
·
Jul 07

Vaxcyte COO Jim Wassil Sells 2,250 Common Shares for $127,708.38

Reuters
·
Jul 07

Vaxcyte CEO Grant Pickering Disposes of USD 1.3 Million in Common Shares

Reuters
·
Jun 27

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Vaxcyte (PCVX)

TIPRANKS
·
Jun 26

Vaxcyte Announces Board Transition and New Director Appointment

TIPRANKS
·
Jun 24

Vaxcyte files initial beneficial ownership statement for director Moncef Slaoui

Reuters
·
Jun 24

Vaxcyte names Moncef Slaoui to board after Jacks Lee retirement

Reuters
·
Jun 24

Mizuho Securities Sticks to Its Buy Rating for Vaxcyte (PCVX)

TIPRANKS
·
Jun 21

Vaxcyte (PCVX) Is Up 8.4% After Starting First-in-Human Trial Of Its Strep A Vaccine

Simply Wall St.
·
Jun 19

Vaxcyte President, CFO Andrew Guggenhime sells 10,000 shares for $530,000

Reuters
·
Jun 19

Vaxcyte Shareholders Reelect Directors, Approve Governance Measures

TIPRANKS
·
Jun 17

Vaxcyte shareholders re-elect three Class III directors at annual meeting

Reuters
·
Jun 17

Vaxcyte’s New VAX-A1 Trial: Early Move Into Group A Strep Vaccines

TIPRANKS
·
Jun 17